Celularity Inc (CELU) - Dilution Analysis

10-K filing | 28.9M shares outstanding

S-1 filing: The selling stockholders are offering on a resale basis an aggregate of up to 15,945,039 shares of Class A common stock of Celularity Inc.

10-Q filing | 26.3M shares outstanding

8-K filing: Celularity Inc. entered into a Securities Purchase Agreement to issue and sell Series A Convertible Preferred Stock and accompanying warrants in a private placement, with an initial tranche closing on October 24, 2025, resulting in gross proceeds of $2 million. ($2.0M proceeds)

10-Q filing | 26.7M shares outstanding

8-K filing: Celularity Inc. entered into a securities purchase agreement for the issuance and sale in a private placement of 739,286 shares of Class A common stock at $1.40 per share, with gross proceeds expected to be $1,035,000. ($1.04M proceeds)

8-K filing: Celularity Inc. issued 100,000 shares of restricted common stock to YA II PN, Ltd. in exchange for extending the maturity date of a convertible promissory note.

10-K filing | 21.9M shares outstanding

8-K filing: Celularity Inc. issued 100,000 shares of its Class A common stock to Yorkville in connection with an extension of the maturity date of a convertible note and a forbearance agreement.

RW filing: Celularity Inc. is withdrawing the registration statement and confirms that no securities were sold in connection with the offering.

8-K filing: Celularity Inc. entered into binding term sheets with Resorts World Inc Pte Ltd and C.V. Starr & Co., Inc. to extend forbearance agreements and issue warrants.

S-1/A filing: Celularity Inc. is offering up to 4,629,629 shares of Class A common stock and up to 4,629,629 pre-funded warrants to purchase up to 4,629,629 shares of Class A common stock at an assumed public offering price of $2.16 per share.

S-1 filing: Celularity Inc. is offering up to 6,521,739 shares of Class A common stock at an assumed public offering price of $2.30 per share, the last reported sale price of our Class A common stock as reported on The Nasdaq Capital Market on January 23, 2025, and up to 6,521,739 pre-funded warrants to purchase up to 6,521,739 shares of our Class A common stock.

8-K filing: Celularity Inc. agreed with warrant holders to amend the exercise price of warrants to $2.07 per share from $2.49 per share and the holders agreed to exercise the warrants for gross proceeds to the Company of approximately $2.46 million. ($2.46M proceeds)

8-K filing: Celularity Inc. entered into a securities purchase agreement for the issuance and sale of 1,263,157 shares of Class A common stock and warrants to purchase up to 1,263,157 shares at $2.375 per share, with gross proceeds expected to be $3.0 million, with the closing expected to occur during the week of January 6, 2025. ($3.0M proceeds)

10-Q filing | 22.0M shares outstanding

10-Q filing | 21.8M shares outstanding

10-Q filing | 21.4M shares outstanding

10-K filing | 22.0M shares outstanding

8-K filing: Celularity Inc. entered into a Standby Equity Purchase Agreement with YA II PN, LTD, issuing a convertible promissory note, commitment shares, and agreeing to forbearance agreements with RWI and Starr, while also issuing a warrant to RWI and adjusting exercise prices of warrants held by Starr due to a prior reverse stock split.

8-K filing: Stock split 1-for-10 | Outstanding: 188,317,262 → 21,782,861

10-Q filing | 188.3M shares outstanding

8-K filing: Celularity Inc. issued 2,707,308 shares of Class A common stock to Yorkville in connection with the extension of the maturity date of the Pre-Paid Advance Agreement.

10-Q filing | 176.6M shares outstanding

8-K filing: Celularity Inc. entered into an amended and restated senior secured loan agreement with Resorts World Inc Pte Ltd, providing for an additional loan and the issuance of warrants to acquire up to 3,000,000 shares of Celularity's Class A common stock at a purchase price of $0.125 per share, closing on June 21, 2023. ($0.38M proceeds)

S-3 filing: This prospectus relates to the offer and sale from time to time by the selling securityholders named in this prospectus of an aggregate of up to 32,086,487 shares of our Class A common stock.

10-Q filing | 180.5M shares outstanding

8-K filing: Celularity Inc. completed a private placement on May 18, 2023, selling 5,813,945 shares of Class A common stock and accompanying warrants to purchase up to 5,813,945 shares of Class A common stock for an aggregate purchase price of approximately $3.75 million. ($3.75M proceeds)

10-K filing | 149.8M shares outstanding

8-K filing: Celularity Inc. entered into a securities purchase agreement for a private placement of 9,381,841 shares of Class A common stock and warrants to purchase up to 9,381,841 shares, and also closed a loan agreement with C.V. Starr & Co. Inc. for $5.0 million and the sale of warrants to acquire up to 750,000 shares of Class A common stock. ($10.08M proceeds)

10-Q filing | 142.7M shares outstanding

POS AM filing: This prospectus relates to the offer and sale from time to time by the selling securityholder named in this prospectus of an aggregate of up to 8,108,110 shares of our Class A common stock.

POS AM filing: This is a POS AM filing for Celularity Inc. registering the issuance of Class A common stock upon exercise of warrants and the resale of Class A common stock and Private Placement Warrants by selling securityholders.

S-3 filing: The company may offer and sell up to $450,000,000 of Class A common stock, preferred stock, debt securities, warrants, and/or units in any combination.

10-Q filing | 140.2M shares outstanding

S-1 filing: This S-1 filing relates to the offer and sale of up to 8,108,110 shares of Class A common stock by the selling securityholder, including shares issuable upon the exercise of warrants.

RW filing: This is a request to withdraw the registration statement on Form S-1 initially filed on April 29, 2022, as the company is no longer pursuing a public offering of its securities at this time.

10-Q filing | 138.3M shares outstanding

S-1/A filing: This S-1/A filing registers for sale 10,533,707 units, each consisting of one share of Class A common stock and one warrant to purchase one share Class A common stock. It also registers the representative’s warrants as a portion of the underwriting compensation.

S-1 filing: This S-1 filing details an offering of Class A common stock with an option for underwriters to purchase additional shares, and includes information on outstanding shares and the use of proceeds.

POS AM filing: The prospectus relates to the issuance of Class A common stock upon exercise of warrants and the offer and sale of Class A common stock and private placement warrants by selling securityholders.

10-K filing | 137.7M shares outstanding

10-Q filing | 123.6M shares outstanding

10-Q filing | 123.5M shares outstanding

S-1 filing: This S-1 filing includes the offering of Class A Common Stock and warrants to purchase Class A Common Stock, as well as the resale of Class A Common Stock by selling securityholders.

10-Q filing | 28.8M shares outstanding

10-K filing | 28.8M shares outstanding

8-K filing: GX Acquisition Corp. entered into a Merger Agreement with Celularity Inc., and concurrently with the execution of the Merger Agreement, GX entered into separate subscription agreements with PIPE Investors to purchase an aggregate of 8,340,000 shares of GX Class A Common Stock for $10.00 per share. ($83.4M proceeds)

10-Q filing | 1.5M shares outstanding

10-Q filing | 1.5M shares outstanding

10-Q filing | 1.5M shares outstanding

10-K filing | 1.5M shares outstanding